Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 342-351

  Bao, Yanjie ^a,b   Jin, Yi ^b   Chivukula, Padmanabh ^b   Zhang, Jun ^b   Liu, Yun ^b   Liu, Jian ^b   Clamme, Jean Pierre ^b   Mahato, Ram I ^c   Ng, Dominic ^b   Ying, Wenbin ^b   Wang, Yiting ^a   Yu, Lei ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b Biomedical Group   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

endosomal disruption; FVII; gene silencing; hepatic distribution; LNP; PEG C DMA

Indexed keywords

MACROGOL 2000; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DISRUPTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; FLUORESCENCE ACTIVATED CELL SORTING; FVII GENE; GENE; GENE EXPRESSION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL; MALE; MOUSE; NANOANALYSIS; NANOPHARMACEUTICS; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; FACTOR VII; HEPATOCYTES; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYETHYLENE GLYCOLS; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84873418330     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0874-6     Document Type: Article

References (41)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990;2(4):279-89.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-11.
3. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28(11):570-9.
4. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2-3):75-86.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
6. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007;13(4):431-56.
7. Lu PY, Woodle MC. Delivering small interfering RNA for novel therapeutics. Methods Mol Biol. 2008;437:93-107.
8. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343-9.
9. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci. 2005;30(2):106-14.
10. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer. 1998;78(2):189-97.
11. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21.
12. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2005;312(3):1020-6.
13. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539-51.
14. Needham D, Kim DH. PEG-covered lipid surfaces: bilayers and monolayers. Colloids Surf B Biointerfaces. 2000;18(3-4):183-95.
15. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994;1190(1):99-107.
16. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. Biochim Biophys Acta. 2002;1564(2):343-8.
17. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids. 2005;135(2):117-29.
18. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000;34(7-8):915-23.
19. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235-7.
20. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release. 2005;107(2):276-87.
21. Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005;1669(2):155-63.
22. Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer. 2012;131(5):E781-90.
23. Foster DJ, Barros S, Duncan R, Shaikh S, Cantley W, Dell A, et al. Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA. 2012;18(3):557-68.
24. Heyes J, Hall K, Tailor V, Lenz R, MacLachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release. 2006;112(2):280-90.
25. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther. 2009;17(5):872-9.
26. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res. 2005;22(3):362-72.
27. MacLachlan I. Antisense Drug Technology: Principles, Strategies, and Applications: CRC Press; 2008.
28. Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, Lazou JM, et al. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology. 1998;27(2):590-8.
29. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431-42.
30. Yessine MA, Lafleur M, Meier C, Petereit HU, Leroux JC. Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochim Biophys Acta. 2003;1613(1-2):28-38.
31. Murthy N, Robichaud JR, Tirrell DA, Stayton PS, Hoffman AS. The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release. 1999;61(1-2):137-43.
32. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161(2):152-63.
33. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8.
34. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111-4.
35. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008;15(17):1193-9.
36. Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M, et al. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59(1):15-22.
37. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066(1):29-36.
38. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-27.
39. Yan X, Scherphof GL, Kamps JA. Liposome opsonization. J Liposome Res. 2005;15(1-2):109-39.
40. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172-6.
41. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357-64.